LOGO
LOGO

Quick Facts

Viatris: Mylan No Longer Subject Of Generic Drug Industry Antitrust Investigation

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

Viatris (VTRS) announced the Antitrust Division of the U.S. Department of Justice has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. Also, the Civil Division of the DOJ informed the company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.

The company said it is pleased to put the DOJ investigations behind it and will continue to move forward to vigorously defend itself against the remaining civil lawsuits pertaining to these matters.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update: April 20 – April 24, 2026

April 24, 2026 15:15 ET
Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.